

FOUNDER

- Peter A. Jensen, MFA, President & CEO

DISCLOSURES

- Why. How. What.
- mRNA Universal Coronavirus Vaccine (UCV) by NORVAX UK and mRNA UCV Consortium
- mRNA Vaccine Platform by Norsk Vaksinefabrikk
- mRNA UCV Consortium by NORVAX UK (ECAM Vaccines Ltd.)
- Current Engagements
- Our Social Principles
- Code of Conduct – Norvax ethical framework
- About Governance. Euronext Growth Rules.
- About MY ECAM

STRATEGIC TECHNOLOGY PARTNERS AND PREFERRED VENDORS

- AmpTec/Merck
- Cytiva
- Emtunga/AFRY
- eTheRNA
- IQVIA
- Merck
- SINTEF
- Syntegon
- Watson-Marlow
- WSP

PRESS

- Norvax in the News in Norway
- PR Agent: Maren Bækkelund Ellingsen WergelandApenes. mbe@wask.no +47 901 77 951

ON SOCIAL MEDIA

- [Twitter](#) and [LinkedIn](#)

MEMBER OF

- Legemiddelindustrien and Norsk Industri

AUDITOR

- PwC Norway

LEGAL ADVISORS

- Tenden Advokatfirma

NORSK VAKSINEFABRIKK SUPPORTED BY

- Innovation Norway
- The Research Council of Norway

NORVAX AS. COMPANY INFORMATION

- Borgeskogen 65, 3160 Stokke, Vestfold og Telemark, Norway
- Company No. 925 541 834
- Contact: peter.jensen@ecambiomed.com

ONLINE

- norvax.no
- mrnaucv.com